| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00378-9045-01 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Aug 15, 1994 | Sep 4, 2018 | In Use | |
| 00002-5337-63 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 5, 2020 | In Use | |
| 50242-0140-86 | 50242-0140 | Vismodegib | Erivedge | 150.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Apr 9, 2013 | In Use | |
| 72205-0082-30 | 72205-0082 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
| 43598-0671-11 | 43598-0671 | Fosaprepitant | Fosaprepitant | 150.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Mar 20, 2020 | In Use | |
| 69097-0949-03 | 69097-0949 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 1, 2023 | In Use | |
| 71332-0005-01 | 71332-0005 | Olutasidenib | REZLIDHIA | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Dec 1, 2022 | In Use | |
| 00004-1100-75 | 00004-1100 | Capecitabine | Xeloda | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 30, 1998 | Dec 31, 2014 | No Longer Used |
| 50242-0064-01 | 50242-0064 | Erlotinib Hydrochloride | Tarceva | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2005 | In Use | |
| 60505-3801-02 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 23, 2025 | In Use | |
| 60505-3801-07 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 69097-0031-56 | 69097-0031 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 00006-5033-02 | 00006-5033 | Trastuzumab | Ontruzant | 150.0 mg/1 | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Apr 15, 2020 | Sep 30, 2023 | No Longer Used |
| 46708-0567-90 | 46708-0567 | ERLOTINIB HYDROCHLORIDE | ERLOTINIB HYDROCHLORIDE | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jul 9, 2021 | In Use | |
| 24987-0111-14 | 24987-0111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jul 15, 2013 | Aug 31, 2017 | No Longer Used |
| 00591-4385-79 | 00591-4385 | fosaprepitant | Fosaprepitant | 150.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sep 19, 2019 | In Use | |
| 78206-0147-01 | 78206-0147 | trastuzumab | Ontruzant | 150.0 mg/1 | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 1, 2021 | In Use | |
| 00078-0708-91 | 00078-0708 | Alpelisib | PIQRAY | 150.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | |
| 69097-0577-73 | 69097-0577 | nilotinib | NILCEYA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2025 | In Use | |
| 00088-1111-14 | 00088-1111 | Nilutamide | Nilandron | 150.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Sep 19, 1996 | Mar 31, 2015 | No Longer Used |
| 16729-0072-12 | 16729-0072 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 9, 2015 | In Use | |
| 65162-0843-06 | 65162-0843 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 10, 2017 | Feb 1, 2024 | No Longer Used |
| 70771-1523-09 | 70771-1523 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
| 72205-0238-64 | 72205-0238 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 20, 2025 | In Use | |
| 62756-0238-88 | 62756-0238 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sep 1, 2019 | In Use |
Found 12250 results — Export these results
Home